Stockwatch: All that glisters is not gold
This article was originally published in Scrip
Executive Summary
Reporting its first quarter 2011 financial results, Pfizer gave investors a hint of how it was dealing with ex-US generic competition to its blockbuster lipid-lowering drug, Lipitor before it has to face that challenge at home later this year.